Ovid Therapeutics Inc
OVID
Get informed when a big investor buys or sells
+ FollowMarket Cap$522.59M
Close$
$-1.81
164.9% downside
Current Fair Value
164.9% downsideOvervalued by 164.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $522.59 Million |
|---|---|
| Enterprise Value | $523.98 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.24 |
| Beta | 0.23 |
| Outstanding Shares | 73,735,606 |
Return
| Return on Equity | -16.43% |
|---|---|
| Return on Assets | -14.87% |
| Return on Invested Capital | -26.45% |
Valuation & Multiples
| P/E Ratio | -5.83 |
|---|---|
| PEG | -2.65 |
| Price to Sales | - |
| Price to Book Ratio | 1.39 |
| Enterprise Value to Revenue | 331 |
| Enterprise Value to EBIT | -8.92 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$64,286
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$23,667
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6257▲ 137.34% |
|---|---|
| Total Calls | 110,600▼ 10.01% |
| Total Puts | 179,800▲ 480.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 142.49%▲ 58.58% |
|---|---|
| Total Invested | $233.18M▲ 131.58% |
| Investors Holding | 109▲ 19.00% |
ESG Score
No data
About Ovid Therapeutics Inc
CEO: Jeremy Levin